A Single Dose Study of MK-8266 (MK-8266-001)

NCT01025791 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: MK-8266 0.1 mg
DRUG: MK-8266 1.0 mg
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC